Dubai Investments PJSC (DIC.AE), a diversified UAE-based investment conglomerate founded in 1995 and headquartered in Dubai Investments Park, Dubai, United Arab Emirates, manages a broad portfolio across real estate, manufacturing, healthcare, education, financial services, building materials, construction, and other sectors; key subsidiaries and investments include Dubai Investments Park for mixed-use developments, Dubai Investment Real Estate for residential and commercial projects, Globalpharma for generic pharmaceuticals, Kings College Hospital London in Dubai and Clemenceau Medical Centre for healthcare services, Al Mal Capital for investment banking and asset management, Emicool for district cooling, Emirates Float Glass and related entities for glass and aluminum products, and Africa Crest Education Fund for educational investments, with operations spanning the UAE, Angola, Saudi Arabia, and other regional markets. The company manufactures construction materials such as float glass, architectural glass, aluminum extrusions, steel structures, polystyrene insulation, and lighting products; provides real estate development and leasing, district cooling services, IT managed solutions through TechSource, owners association management via Al Mujama and PIDOAM, and sports management through QDI; and holds stakes in insurance via National General Insurance Company and fertility services via Global Fertility Partners. In recent developments, Dubai Investments reported a 59% surge in profit before tax to AED 1.10 billion for the nine months ended 30 September 2025, with total assets reaching AED 23.57 billion; acquired over 34% stake in Global Fertility Partners and 21.53% shares via a direct deal on the Dubai Financial Market in 2024-2025; and continues strategic diversification including Al Mal Capital REIT launched in 2021, alongside divestment processes to unlock value and facilitate growth in non-oil sectors.